Skip to main content
. 2020 Nov 1;10(11):3882–3895.

Figure 2.

Figure 2

Comparison of HCC incidence between entecavir and TDF according to the PS-matching or IPTW method. All patients (A) and (B), compensated cirrhotic patients (C) and (D), and patients enrolled after 2011 (E) and (F). Abbreviations: IPTW, inverse probability of treatment weighting; HCC, hepatocellular carcinoma; TDF, tenofovir disoproxil fumarate; PS, propensity score.